Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Better access. Better health
Read our guide to Generic and biosimilars medicines market and pricing
Better access to high quality biological medicines
The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars

The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars.

The members of the BBA ensure access to high quality, safe and effective biosimilar medicines for UK patients. As industry experts, we partner with patients’ representatives, healthcare professionals, regulators and payers to increase understanding and to drive a sustainable environment for the development, production and continuing optimised use of biosimilar medicines across the UK.

For more information about Biosimilars, please take a look at NHS England’s ‘What is a Biosimilar’ document.

Twitter

28.11.2019
RT @biosciencetoday: Biosimilar medicines are playing an important role in providing choice for clinicians and increasing access for patients by driving down cost to the NHS. @BritBiosimilars https://t.co/2tdxdhSPAZ
28.11.2019
Read our statement in full in response to claims that the NHS could be part of any free trade agreement with the US and what it would mean for generic and biosimialr medicines. https://t.co/rWONcD3jnj
01.11.2019
RT @Britishgenerics: We welcome publication of NHS Commercial Framework and look forward to engagement with @NHSEngland and @blakeydark leading up to adoption.
01.11.2019
RT @blakeydark: I'm very excited to share the Commercial Framework for Medicines. We welcome all comments to the engagement process. https://t.co/lpWNdHVbnO
01.11.2019
RT @Sandoz_Global: We are proud to announce that Isabell Remus, our Head Region Europe, Biopharmaceuticals, has been elected as the Chair of the #Biosimilar Medicines Group @medicinesforEU, dedicated to providing sustainable access to high quality medicines for all patients.